A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

Inclusion criteria

• Males or females 35 to 75 years of age at the time of signing the informed consent form (ICF).
• Considered to be generally healthy based on medical history, physical examination, and the re-sults of vital signs, electrocardiogram, and clinical laboratory tests performed during the screening visit, as judged by the investigator.
• Body mass index (BMI) 20 to 35 kilogram per meter square (kg/m2) (both inclusive) at screening.
• Serum uric acid levels greater than or equal to (≥) 6.8 miligram per decileter (mg/dL) to less than or equal (≤) 12 mg/dL on 2 consecutive screening samples (the first at the screening visit [V1], and the second taken at V2 [day -1]; samples at least 7 days apart).

Exclusion criteria

• Female who is pregnant, breastfeeding, or intends to become pregnant or is of childbearing po-tential and not using an adequate contraceptive method.
• Male of reproductive age who, or whose female partner(s), is not using an adequate contraceptive method.
• Present or prior history of gout, or present or prior use of serum Uric acid (sUA) lowering medication.
• Serious cardiovascular or hepatic disease, current or past malignancies, or chronic debilitating neurologic, gastrointestinal, or inflammatory diseases.
• History or current diagnosis of chronic history kidney disease.
• Screening alanine transaminase (ALT) or aspartate aminotransferase (AST) values greater than (>) 2 multiply by (×) upper limit normal (ULN) or total bilirubin >1.5× ULN.